Can-Fite BioPharma (NYSE:CANF) Stock Rating Upgraded by StockNews.com

Can-Fite BioPharma (NYSE:CANF) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

Several other equities analysts have also recently commented on CANF. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Can-Fite BioPharma in a research note on Tuesday. EF Hutton Acquisition Co. I raised Can-Fite BioPharma to a “strong-buy” rating in a research report on Wednesday, July 17th.

Can-Fite BioPharma Trading Down 0.5 %

Shares of CANF stock opened at $2.07 on Tuesday. The firm has a 50-day moving average price of $2.26 and a 200 day moving average price of $2.52. Can-Fite BioPharma has a twelve month low of $1.83 and a twelve month high of $4.69. The company has a market capitalization of $7.33 million, a price-to-earnings ratio of -1.16 and a beta of 1.39.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC boosted its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the quarter. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. 21.00% of the stock is currently owned by institutional investors and hedge funds.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.